Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape in oncology.
However, ICI can induce uncommon life-threatening autoimmune T-cell-mediated …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Paraneoplastic neurological syndromes (PNSs) comprise a group of disorders that can
affect any part of the nervous system in patients with cancer and frequently result from …

Objective To report the induction of anti–Ma2 antibody–associated paraneoplastic
neurologic syndrome (Ma2-PNS) in 6 patients after treatment with immune checkpoint …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial
origin characterized by varying degrees of lymphocytic infiltration and a predisposition …